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Summary
a 35-year-old man with juvenile idiopathic arthritis 
since childhood presented with bilateral atypical tibial 
fractures, followed by a later, single atypical fracture of 
the femur. the fractures were associated with 6 years 
of oral alendronate treatment immediately followed by 
subcutaneous denosumab therapy and later teriparatide 
therapy for osteoporosis. atypical fractures are known 
to occur in the femur following bisphosphonate therapy; 
however, there are only a few documented cases of 
atypical fractures in the tibia. our case highlights a rare 
but serious complication of a commonly prescribed 
antiresorptive agent. It also shows that teriparatide, 
while helpful in increasing bone mass, does not fully 
prevent the development of atypical fractures. Careful 
investigation should be considered in patients on 
long-term antiresorptive therapy presenting with bony 
tenderness to exclude an atypical fracture.
BaCkground
Juvenile idiopathic arthritis is associated with tibial 
stress fractures in children,1 but here we present a 
challenging case in an adult, where antiresorptive 
therapy and underlying inflammatory disease may 
have been involved in the pathogenesis of multiple 
lower limb atypical fractures. Bisphosphonates are 
widely prescribed to prevent and treat osteoporosis. 
They have a good safety profile and are highly effec-
tive in increasing bone mass and density, thereby 
reducing fragility fracture risk.2 3 As analogues of 
inorganic pyrophosphate, bisphosphonates readily 
integrate at bone surfaces and induce osteoclast 
apoptosis, thereby suppressing bone resorption and 
increasing bone mass. Denosumab is a monoclonal 
antibody that binds RANK-Ligand, thereby inhib-
iting the recruitment and formation of osteoclasts, 
increasing bone mass and reducing fragility frac-
tures. Both are in the class of ‘antiresorptive drugs’, 
having effects on both resorption and subsequent 
bone formation. Paradoxically, long-term antire-
sorptive use might impair bone remodelling and 
repair, resulting in the progressive accumulation of 
microdamage and increasing the risk of low turn-
over ‘atypical’ stress fractures.4–7 As the primary 
weight-bearing bone during bipedal walking, the 
upper mid-femur appears to be particularly suscep-
tible to developing atypical stress fractures.8–13 
Fractures in other long bones such as the tibia 
have only rarely been reported.14–18 We describe a 
case of a 35-year-old man with juvenile idiopathic 
arthritis since childhood who presented with bilat-
eral atypical tibial fractures, followed by a later, 
single atypical fracture of the femur. The fractures 
were associated with 6 years of oral alendronate 
treatment immediately followed by subcutaneous 
denosumab therapy and later teriparatide therapy 
for osteoporosis.
CaSe preSenTaTion
A 35-year-old Caucasian man with a history of 
glucocorticoid-induced osteoporosis secondary to 
juvenile and continuing adult severe inflammatory 
arthritis took alendronic acid (70mg) weekly for 
6 years continuously. He presented with a symp-
tomatic left anterior tibial stress fracture associated 
with slight anterior bowing of his tibia and evidence 
of endosteal oedema on MRI (figure 1). This was 
managed conservatively, but he presented 7 months 
later with worsening acute pain in his left leg while 
seated. On examination, he had bony tenderness 
of the left mid-distal tibia with difficulty weight-
bearing. There was no history of falls or local 
trauma. Other relevant medications included fort-
nightly adalimumab (40mg), as well as one time per 
day leflunomide (20mg), prednisolone (15mg) and 
etodolac (600mg). There was no history of cigarette 
smoking, no relevant alcohol intake and his body 
mass index (BMI) was below 25. He was ambulant 
without aids prior to his stress fracture but walked 
with an antalgic gait due to severe arthritis affecting 
his ankles and knees bilaterally.
At presentation, the plain X-ray revealed an 
incomplete, non-displaced short oblique fracture in 
the anterior middle-third of the left tibial diaphysis 
associated at the point of maximal anterior bowing 
of the tibia, that is, in a region subjected to high 
tensile forces during gait (figure 2). Bone mineral 
density (BMD) T-scores using dual-energy X-ray 
absorptiometry (DEXA) were −3.0 at the neck 
of femur and −3.1 at the lumbar spine (a T-score 
of <2.5 is a diagnosis of osteoporosis). He was 
fitted with a fibreglass cast and further conserva-
tive management was tried. Before coming under 
our care, his osteoporosis therapy was switched to 
subcutaneous denosumab 60mg 6-monthly due to 
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concerns that alendronic acid may have interfered with fracture 
healing. A time frame of the events following this fracture is 
available in figure 3.
He continued to exhibit poor fracture healing over a year later. 
X-rays showed that the fracture line was still visible, with ongoing 
pain and no evidence of bone union. Teriparatide injections were 
commenced. Adalimumab was increased to 40mg weekly due to 
significant joint pain from active arthritis. Etodolac was stopped. 
Two months later, he developed a strikingly similar atypical frac-
ture, this time in his right tibia (figure 2). Both tibiae were fixed 
with anterior tibial plates and screws.
He presented again 4 months postrepair with spontaneous 
bilateral periprosthetic transverse fractures that occurred 
suddenly while walking up the stairs at work. The tibial plates 
were removed, and the tibiae were fixed with intramedullary 
nails instead. A subsequent review showed a good postoperative 
result with the anterior bowing of his tibiae corrected after 
nailing. Adalimumab was switched to tocilizumab due to wors-
ening arthritis, but teriparatide injections were stopped after 
18 months as he developed recurrent infections around the 
injection site. A DEXA scan demonstrated that his Z-scores had 
improved to −2.3 at the lumbar spine but only to −2.8 at the 
femoral neck. He was commenced on risedronate 35mg once 
weekly to maintain BMD gains induced by teriparatide.
One and half years later, he sustained a right femoral fracture 
(figure 4) associated with, but not necessarily caused by, a fall 
from standing height. X-rays showed a short oblique fracture 
at the proximal femoral diaphysis with cortical beaking. The 
fracture was treated with intramedullary nail fixation. A tran-
siliac crest bone biopsy was subsequently taken following double 
tetracycline labelling to assess bone turnover. There was no 
evidence of malignancy, osteomalacia nor absent populations of 
osteoclasts. Bone volume over total volume was 17.2% (normal 
range: 16.4%–24.8%). Tetracycline labelling showed normal 
mineralisation and high bone turnover, with no suggestion of 
oversuppression (figure 5).
ouTCome and follow-up
Our patient has since recovered well from his fractures and 
continues to receive regular follow-up with his rheumatologist.
figure 1 Lateral tibial X-ray obtained at the first visit (A). Sagittal 
fat-supressed proton density-weighted image showed endosteal 
oedema (arrowhead) (B). Axial fat-suppressed fast spin echo (C) and 
T1-weighted image (D) did not show focal cortical thickening. Markers 
(C,D) showed the region of prodromal pain. High intensity (B,C) and low 
intensity (D) signals in bone marrow represent endosteal oedema.
figure 2 Time course of an atypical fracture of the left (A–D) and 
right (E–H) tibia in lateral (A,B,E,F) and anteroposterior (C,D,G,H) views. 
(A,E) Similar mid-shaft fractures across the anterior cortex of the left 
and right tibial diaphysis. The fracture line originated transversely 
and became oblique as it progressed posteriorly across the tibia; (B,F) 
fractures 1 month after repair with tibial plates; (C,G) subsequent 
periprosthetic fractures; (D,H) final fracture repair with medullary nails.
figure 3 Timeline of events following initial presentation with left 
anterior tibial stress fracture.
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diSCuSSion
There is a growing body of evidence linking long-term bisphos-
phonate use with atypical femoral fractures. Although initial 
registry studies found no correlation between bisphospho-
nate use and the rate of subtrochanteric or femoral shaft frac-
tures,19–21 such studies have been criticised for overrelying on 
diagnostic codes, which fail to adequately distinguish atypical 
femoral fractures from other fractures.22 23 Conversely, most 
studies utilising radiographic data have demonstrated a strong 
association between bisphosphonates and atypical femoral frac-
tures.22–24 A subsequent meta-analysis assessing data from both 
registry and radiographic studies has also shown an increased 
risk of subtrochanteric, femoral shaft and atypical femoral frac-
tures with bisphosphonate usage.25
Atypical insufficiency fractures of the tibia, on the contrary, 
are much less common. There are only a few case reports avail-
able which describe insufficiency fractures occurring in the 
tibial diaphysis14–16 and metaphysis17 18 of patients on long-term 
bisphosphonate therapy (table 1). The American Society for Bone 
and Mineral Research (ASBMR) has specific guidelines, which 
delineate the criteria for atypical insufficiency fractures.26 27 
However, this definition is strictly limited to femoral fractures 
and is not designed for fractures in alternative sites. Save for 
its location in the distal tibia, our case matches all major and 
multiple minor ASBMR criteria for atypical fractures. Key 
features include presenting with bilateral transverse, non-com-
minuted tibial fractures following no trauma, with delayed frac-
ture healing and prodromal pain for several months leading up 
to the fracture.
The pathogenesis of atypical tibial fractures is unclear. In our 
patient, abnormal anterior tibial bowing could have led to altered 
biomechanical forces across the tibia, resulting in the develop-
ment of microfractures along the anterior cortex. These were mild 
bilateral shape abnormalities, which might have been caused by 
the effects of juvenile arthritis on bone development rather than 
a true deformity (such as congenital pseudoarthrosis). It has been 
hypothesised that micromovements within a fracture can inhibit 
cellular remodelling and that osteoclast-mediated widening of 
the fracture gap is required before bone formation can occur.23 
Excessive osteoclast inhibition through long-term bisphospho-
nate and antiresorptive therapy could therefore predispose to 
the development of atypical insufficiency fractures. The duration 
of bisphosphonate usage has been strongly correlated with the 
risk of atypical femoral fractures.28 29 In a recent large cohort 
study, it was found that patients on bisphosphonates for over 
8 years were more than 40 times more likely to develop atypical 
femoral fractures compared with patients with less than 1 year 
of usage.30 However, care should be taken when extrapolating 
these findings to tibial fractures. There is no current consensus 
on how to mitigate the risk of atypical fractures in long-term 
treated patients such as ours, who have a very substantial burden 
of severe osteoporotic disease, ongoing moderate steroid usage 
and in whom most guidelines would advocate continual treat-
ment rather than a bisphosphonate break.
Other risk factors that may have contributed to his atypical 
fractures include the corticosteroid use itself and inflammatory 
arthritis. Denosumab, while certainly useful in the treatment 
of osteoporosis and prevention of fragility fractures, might in 
his case have led to accumulation of microfractures through 
blocking RANK-Ligand. Denosumab-associated atypical frac-
tures following treatment for osteoporosis have been previously 
reported31–33 although these cases are uncommon. The extent to 
which any or all of these risk factors may have contributed to the 
development of his fractures remains uncertain.
The other point of interest in our case is the development 
of an atypical femoral fracture after our patient was started 
on risedronate treatment following completion of teri-
paratide therapy. Teriparatide has been shown to be effective 
in improving bone mass and reducing fracture healing time 
in atypical fractures secondary to bisphosphonate usage.34–36 
However, similar cases of atypical femoral fractures occurring 
with the recommencement of antiresorptive agents following 
teriparatide therapy have previously been reported.37 38 It has 
been suggested that teriparatide may not be fully able to coun-
teract the long-term effects of bisphosphonates on bone or that 
the reintroduction of antiresorptives could also be implicated 
in the recurrence of atypical fractures.37 Histomorphometry 
of our patient’s iliac crest biopsy has shown no evidence of 
oversuppression of bone turnover to account for his atyp-
ical fracture. This runs contrary to several reports that have 
demonstrated markedly reduced bone turnover in bisphospho-
nate-treated patients suffering from atypical fractures.5 6 8 16 
There has been a case report that has shown no evidence of 
adynamic bone in a patient with atypical femoral fractures; 
however, the biopsy specimen was taken from near the fracture 
figure 4 Anteroposterior radiographs of an atypical insufficiency 
fracture of the right proximal femur. There is a transverse fracture line 
that becomes oblique as it progresses laterally across the femoral cortex 
with a medial spike (A). X-ray 2 months later after intramedullary nailing 
(B). Highly magnified area (C) showing evidence of periosteal and 
endosteal callus reaction.
figure 5 (A) Light micrograph of a section stained with toluidine 
blue from a transiliac bone biopsy taken after double tetracycline 
labelling. Osteoid seams were detected on trabeculae (arrow heads). (B) 
Fluorescence micrograph showing tetracycline-labelled bone surfaces 
corresponding with osteoid surfaces (arrow heads). Scale bars: 150 µm.
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site, which may have locally elevated bone turnover rates.39 
The high rates of bone turnover in our case are most likely due 
to the effects of prior teriparatide therapy on stimulating bone 
formation, although it appears that this does not prevent the 
formation of atypical fractures.
In summary, atypical fractures potentially associated with 
antiresorptive therapy can occur in weight-bearing long bones 
other than the femur. Moreover, teriparatide usage does not 
prevent the development of atypical fractures. Given the low 
incidence of bisphosphonate-related atypical fractures and good 
evidence that benefits outweigh risks if appropriate ‘bisphos-
phonate holidays’ are taken, findings from this case should not 
be extrapolated to other patients taking antiresorptives beyond 
5 years. However, bony femoral or tibial tenderness in a patient 
on long-term antiresorptive treatment should prompt careful 
investigation to exclude an atypical fracture. Current guidelines 
are unclear about the optimal treatment of severe osteoporosis 
after an atypical fracture, and new strategies may be required to 
prevent ongoing harm in patients such as this.
learning points
 ► Atypical fractures in the tibia can be a potential complication 
of long-term antiresorptive therapy.
 ► Teriparatide, while helpful in increasing bone mass, does not 
fully prevent the development of an atypical fracture.
 ► Careful investigation should be considered in patients 
on long-term antiresorptive agents presenting with bony 
tenderness to exclude an atypical fracture.
 ► Appropriate ‘bisphosphonate holidays’ should be taken to 
minimise the risk of developing atypical fractures.
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